- 11th - 12th April 2024
- Hilton London Kensington, London, United Kingdom
21st Orphan Drugs & Rare Diseases Global Congress 2024
Collaborations to Accelerate Rare Disease Drug Development and Access
- 00Days
- 00Hours
- 00Minutes
- 00Seconds
The Fastest Growing Orphan Drugs & Rare Diseases Networking Event.
Facilitate Live is proud to present our Orphan Drugs and Rare Diseases Global Congress 2024 Europe. It’s the 21st in the series of our Flagship tri-annual Orphan Drugs & Rare Diseases event. This congress will provide you with a comprehensive
overview of the critical issues shaping the future of Orphan Drugs.
The COVID-19 Pandemic has impacted the lives of just about everyone, patients receiving
continuous treatment and care included. The Rare Disease community is already
experiencing considerable challenges in achieving early and detailed diagnosis and having
access to care and life-saving treatment, to chronic, highly complex, progressive, and
severely disabling nature of their diseases, which generate specific care needs. Undoubtedly,
during this crisis, the rare diseases community is experiencing unprecedented overall disruption even more…
According to a report by Fortune Business Insights, the Global Orphan Drugs Market size
will emerge from the COVID-19 crisis at a moderate growth during the forecast period of
2020 to 2026. The global orphan drugs market size is projected to reach USD 340.84 billion
by the end of 2027. As stated, the market was worth USD 151.00 billion in 2019 and will
exhibit a CAGR of 10.5% during the forecast period, 2020-2027.
The current regulatory climate increasing the number of regulatory approvals, expanding numbers of successful clinical trials related to these drugs, tremendous investments in R & D, and the interest and existence of several large-scale manufacturers, will create opportunities and contribute exponentially to the overall market growth.
The two-day Congress will provide an interactive, cutting edge, and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies, and concepts surrounding orphan drugs and rare diseases.
We look forward to meeting you at the Congress!
Sincerely yours,
Jocelyn Raguindin
Conference Director
Facilitate Live
GAIN LATEST INSIGHTS ON:
WHO SHOULD ATTEND?
This congress is specially created for valued stakeholders in the Rare Disease community:
Network with Presidents, Heads/Chiefs, VPs, Directors, and Managers in the area of:
President of Innovation, Research, & World Clinic
Chief Medical Officer, Gene Therapy and Inborn Errors of Metabolism
Director for Global Regulatory & Scientific Policy (GRASP)
CSO & General Manager
CEO
President and CEO
CEO
Chief Commercial Officer
Operations Lead
Senior Projects Officer
Founder & CEO
Director, Patient Advocacy
EVP Commercial
Head of Value & Access Oncology, APAC, MEA
Head of Medicine, Life Sciences Division
Chief Medical Officer
Group CEO
Rare Diseases Clinical Lead, National Disease Registration Service
Head of Expanded Access
Content Rich Program Agenda! Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.
Robert Mitchell-Thain, CEO, PBC Foundation
Nicola Gillott, Head of Expanded Access, Amryt Pharma
Pedro Franco, Director for Global Regulatory & Scientific Policy (GRASP), Merck
Graham Sidorowicz, EVP Commercial, Bionical Emas
Kristin Smedley, CEO, Curing Retinal Blindness Foundation
Regulatory Challenges on Early Access Programmes
Pedro Franco, Director for Global Regulatory & Scientific Policy (GRASP), Merck
Graham Sidorowicz, EVP Commercial, Bionical Emas
Naomi Litchfield, Director, Patient Advocacy, Bionical Emas
Florence Barkats, Chief Commercial Officer, CISIV Ltd
Bob Stevens, Group CEO, MPS Society/Rare Disease Research Partners
Robert Palmer, Head of Value & Access Oncology, APAC, MEA, Novartis
Hannah Stark, Operations Lead, NIHR BioResource
Pr Daniel Scherman, Head of Medicine, Life Sciences Division, European Academy of Sciences EURASC
Manolo Bellotto, CSO & General Manager, Gain Therapeutics
Hannah Stark, Operations Lead, NIHR BioResource
Anthony Hall, Chief Medical Officer, Healx
Manolo Bellotto, CSO & General Manager, Gain Therapeutics
Pedro Franco, Director for Global Regulatory & Scientific Policy (GRASP), Merck
Robert Mitchell-Thain, CEO, PBC Foundation
Sponsored by:
Josie Godfrey, Director, JG Zebra Consulting, Joint CEO, Realise Advocacy
Peter Lanyon, Rare Diseases Clinical Lead, National Disease Registration Service, NHS England
David Pearce, President of Innovation, Research & World Clinic, Sanford Health
Sheela Upadhyaya, Chair Elect, Rare Disease Special Interest Group, ISPOR
Rüdiger Schulze, VP & GM, Germany & Central/Eastern Europe, Ultragenyx
Josie Godfrey, Director, JG Zebra Consulting, Joint CEO, Realise Advocacy
Moderator:
Florence Barkats, Patient Advocate, NHCollab
Panelists:Lara Bloom, President and CEO, The Ehlers-Danlos Society
Anthony Hall, Chief Medical Officer, Healx
Bob Stevens, Group CEO, MPS Society/Rare Disease Research Partners
Hannah Harvey, Senior Projects Officer, Beacon for Rare Diseases
Robert Mitchell-Thain, CEO, PBC Foundation
Christian Girard, Co-founder, OrphaPedia
Nick Sireau, Chair & CEO, AKU Society
Moderator: Josie Godfrey, Director, JG Zebra Consulting, Joint CEO, Realise Advocacy
Panelists: Anthony Hall, Chief Medical Officer, Healx
Nick Sireau, Chair & CEO, AKU Society
Robert Mitchell-Thain, CEO, PBC Foundation
Josie Godfrey, Director, JG Zebra Consulting, Joint CEO, Realise Advocacy
19th Orphan Drugs and Rare Diseases Global Congress 2023 Europe
No Spam - You will only receive relevant information on Orphan Drugs & Rare Diseases, and event updates
what people say
Take Advantage of the Super Early Bird Discount. Group Discounts Also Available.